Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
New Dilution of Dysport for Glabellar Lines
NCT03960957Phase 3Completed
- Sponsor
- Galderma
- Start
- Jun 2019
- Primary completion
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in glabellar lines comparing Dysport with Placebo (2 arms). Primary endpoint: Composite Responder Rate at Month 1. Started Jun 2019; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT03960957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03960957.